Advertisement
NRBO Berita Forex
NeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8%
Biotechnology company NeuroBo Pharmaceuticals, Inc. (NRBO) announced Wednesday the receipt of Safety Review Committee (SRC) approval, recommending that the two-part Phase 2a trial of DA-1241 can continue without modification following a blinded safety review of the first six months of study conduct.
RTTNews
|
534 hari yang lalu
NeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFO
Biotechnology company NeuroBo Pharmaceuticals, Inc. (NRBO) announced Monday the appointment of Marshall Woodworth as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective March 1, 2024, following his tenure as Acting Chief Financial Officer since October 27, 2023.
RTTNews
|
543 hari yang lalu
